Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis

Summary

The aim of this observational study is to comprehensively analyze the metabolites in plasma samples from multi-cancer patients using advanced mass spectrometry detection technology, in conjunction with metabolomics approaches. The goal is to construct a plasma metabolite database for multi-cancer patients. Simultaneously, we will delve into the exploration and validation of a series of metabolic biomarkers for early multi-cancer diagnosis. The objective is to establish a safer, more convenient, and more sensitive early screening method, thereby providing a reliable scientific foundation and critical evidence for improving the early diagnostic process for individuals at high risk of multi-cancer.

Eligibility

Inclusion Criteria:

* Multi-Cancer Group:

  * Patients with a confirmed diagnosis based on the clinical "gold standard".
  * Collection of plasma samples prior to treatment.
  * Availability of complete clinical data.
* Control Group:

  * Individuals with no abnormalities in routine physical examinations and relevant clinical tests.
  * Age ≥ 45 years.
  * Availability of complete clinical data.

Exclusion Criteria:

* Previous reception of anti-tumor treatments (including radiotherapy, chemotherapy, etc.) before blood collection.
* Coexistence of other systemic tumors.
* Absence of plasma sample collection before treatment.
* Pregnancy status.
* No clear evidence of histopathological diagnosis (not applicable to the control group based on this criterion).
* Patients with severe acute infections.
* Patients with severe anemia.
* Patients with severe liver or kidney dysfunction.
* Patients with autoimmune deficiency diseases.
* Patients with Hyperlipidemia.
* Patients received contrast agent injection before blood draw.
* Patients with psychiatric disorders.

Conditions15

Browse More Trials